Related Experiment Video
Updated: Feb 16, 2026
05:42
Author Spotlight: Unlocking the Mysteries of Oral Potential Malignancies
Published on: August 11, 2023
1.7K
New oral antidiabetic agents.
Paolo Cavallo Perin1, Paolo Fornengo
1Department of Internal Medicine, University of Torino, Corso AM Dogliotti 14, Turin, Italy. paolo.cavalloperin@unito.it
Internal and Emergency Medicine
|October 20, 2011
Summary
New oral anti-diabetic agents target specific type 2 diabetes (T2DM) defects like insulin deficiency and resistance. Future strategies focus on incretin-based therapies, SGLT2 inhibitors, and glucokinase activators for combination treatments.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes (T2DM) pathophysiology involves insulin deficiency, excess hepatic glucose production, and insulin resistance.
- Oral anti-diabetic agents target these defects through various mechanisms, including stimulating insulin secretion, reducing glucose production, and improving insulin action.
Purpose of the Study:
- To review novel oral anti-diabetic agents and future therapeutic strategies for T2DM.
- To highlight the importance of targeting specific pathophysiological alterations in T2DM management.
Main Methods:
- Focus on recent advancements in oral anti-diabetic drug development.
- Discussion of incretin-based therapies, SGLT2 inhibitors, and glucokinase activators.
- Exploration of combination therapy potential.
Main Results:
- Newer agents offer targeted mechanisms for T2DM pathophysiology.
- Incretin-based therapies, SGLT2 inhibitors, and glucokinase activators represent key advancements.
- Combination therapies hold promise for improved glycemic control.
Conclusions:
- A broad range of anti-diabetic medications with diverse mechanisms is essential.
- Future drug development should focus on effective combination strategies for T2DM.
- Personalized treatment approaches leveraging new drug classes are crucial for managing T2DM.
Related Concept Videos
01:29Subviral Agents
596
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
596
01:06Oral Hypoglycemic Agents: Glinides
700
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
700
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.2K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.2K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
696
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
696
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
608
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
608
01:11Oral Cavity
3.2K
The oral cavity, or the mouth, is a complex structure in humans that plays a vital role in our day-to-day lives. Its role is not only in chewing and swallowing food; it also plays a role in speech and facial expressions.
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
3.2K